Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m

Werewolf, Vaccitech Bring US 2021 Biopharma IPO Total To 40

Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.

Finance Watch

After years of wondering whether founder and executive chairman Vivek Ramaswamy would take Roivant Sciences public, the multi-subsidiary firm will begin trading on the Nasdaq in the third quarter when the company closes its merger with the special purpose acquisition corporation (SPAC) Montes Archimedes Acquisition Corp. (MAAC), which was announced on 3 May.

The deal gives Roivant approximately $611m in new cash, including roughly $411m held in trust by MAAC and $200m from a concurrent private investment in public equity (PIPE) financing at $10 per share, which will extend the company’s operating cash runway through mid-2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Finance Watch

More from Financing

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By 

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’